Table 1 Patient characteristics
Variables | No. of patients (%) |
|---|---|
Sex | |
Male | 97 (81.5) |
Female | 22 (18.5) |
Age (years) | |
Median (range) | 60 (36–90) |
ECOG performance status | |
0 | 102 (85.7) |
1 | 13 (10.9) |
2 | 4 (3.4) |
Child-Pugh class | |
A | 108 (90.8) |
B | 11 (9.2) |
Viral aetiology | |
Hepatitis B virus | 93 (78.2) |
Hepatitis C virus | 11 (9.2) |
Non B, Non C | 15 (12.6) |
Tumor size (cm)a | |
Median | 1.7 |
0.8–1.0 | 8 (5.8) |
1.1–2.0 | 90 (64.7) |
2.1–3.0 | 32 (23.0) |
3.1–4.0 | 8 (5.8) |
5.1–6.0 | 1 (0.7) |
Modified UICC stageb | |
I | 60 (50.4) |
II | 53 (44.5) |
III | 6 (5.0) |
Alpha-fetoprotein (ng/mL) | |
Range | 1.6–4303.6 |
PIVKA-II (mAU/mL) | |
Range | 0–11,501.0 |
No. of prior treatment before SBRT | |
Median (Range) | 3 (0–25) |
Summary of prior treatments | |
None | 3 (2.5) |
TACE | 57 (47.9) |
TACE, RFA | 27 (22.7) |
TACE, PEI | 3 (2.5) |
TACE, RFA, PEI | 1 (0.8) |
TACE, sorafenib | 1 (0.8) |
Resection | 2 (1.7) |
Resection, TACE | 15 (12.6) |
Resection, TACE, RFA | 5 (4.2) |
Resection, TACE, PEI | 2 (1.7) |
Resection, RFA | 2 (1.7) |
PEI | 1 (0.8) |